BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $225,027,754 | -12.8% | 3,305,826 | +4.5% | 0.02% | -8.0% |
| Q2 2023 | $258,123,207 | +9.3% | 3,162,110 | -0.7% | 0.02% | 0.0% |
| Q1 2023 | $236,234,536 | -4.4% | 3,184,182 | +6.8% | 0.02% | -10.7% |
| Q4 2022 | $247,200,463 | +308.7% | 2,982,630 | +1300.4% | 0.03% | +250.0% |
| Q3 2022 | $60,489,000 | -24.3% | 212,988 | -7.6% | 0.01% | -20.0% |
| Q2 2022 | $79,937,000 | +74.5% | 230,604 | +118.0% | 0.01% | +66.7% |
| Q1 2022 | $45,808,000 | -7.0% | 105,776 | +11.2% | 0.01% | 0.0% |
| Q4 2021 | $49,234,000 | -12.0% | 95,165 | -17.6% | 0.01% | -25.0% |
| Q3 2021 | $55,954,000 | +51.9% | 115,471 | +41.1% | 0.01% | +60.0% |
| Q2 2021 | $36,835,000 | +142.8% | 81,809 | +106.0% | 0.01% | +150.0% |
| Q1 2021 | $15,169,000 | -38.3% | 39,712 | -48.7% | 0.00% | -50.0% |
| Q4 2020 | $24,588,000 | +195.8% | 77,432 | +130.8% | 0.00% | +100.0% |
| Q3 2020 | $8,311,000 | -11.5% | 33,553 | -5.6% | 0.00% | 0.0% |
| Q2 2020 | $9,388,000 | -53.8% | 35,556 | -66.8% | 0.00% | -66.7% |
| Q1 2020 | $20,321,000 | +65.8% | 107,169 | +92.0% | 0.01% | +100.0% |
| Q4 2019 | $12,253,000 | +82.9% | 55,818 | +63.0% | 0.00% | +50.0% |
| Q3 2019 | $6,699,000 | -27.2% | 34,235 | -22.4% | 0.00% | 0.0% |
| Q2 2019 | $9,196,000 | -20.1% | 44,109 | -23.9% | 0.00% | -33.3% |
| Q1 2019 | $11,511,000 | +115.5% | 57,980 | +57.1% | 0.00% | +50.0% |
| Q4 2018 | $5,342,000 | -68.6% | 36,914 | -55.8% | 0.00% | -50.0% |
| Q3 2018 | $17,034,000 | -8.0% | 83,453 | -33.3% | 0.00% | -20.0% |
| Q2 2018 | $18,522,000 | +35.1% | 125,195 | +37.9% | 0.01% | +25.0% |
| Q1 2018 | $13,712,000 | -7.4% | 90,775 | -20.6% | 0.00% | 0.0% |
| Q4 2017 | $14,813,000 | +18.0% | 114,345 | +10.1% | 0.00% | 0.0% |
| Q3 2017 | $12,552,000 | +61.0% | 103,823 | +56.4% | 0.00% | +100.0% |
| Q2 2017 | $7,798,000 | -57.4% | 66,364 | -63.2% | 0.00% | -33.3% |
| Q1 2017 | $18,324,000 | +4.7% | 180,252 | +5.9% | 0.00% | 0.0% |
| Q4 2016 | $17,508,000 | +248.6% | 170,276 | +271.3% | 0.00% | +50.0% |
| Q3 2016 | $5,023,000 | -16.9% | 45,864 | -14.5% | 0.00% | 0.0% |
| Q2 2016 | $6,047,000 | +107.4% | 53,620 | +73.9% | 0.00% | +100.0% |
| Q1 2016 | $2,915,000 | +8.1% | 30,838 | +2.9% | 0.00% | 0.0% |
| Q4 2015 | $2,697,000 | -47.5% | 29,964 | -46.1% | 0.00% | -50.0% |
| Q3 2015 | $5,140,000 | -28.2% | 55,595 | -23.5% | 0.00% | 0.0% |
| Q2 2015 | $7,158,000 | +9.0% | 72,685 | +11.0% | 0.00% | 0.0% |
| Q1 2015 | $6,567,000 | -0.6% | 65,483 | -8.4% | 0.00% | 0.0% |
| Q4 2014 | $6,607,000 | – | 71,490 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |